Trial Profile

Phase III, Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of SHR-1209 Monotherapy in Patients With Primary Hypercholesterolemia and Mixed Hyperlipemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jan 2025 According to Guangdong Hengrui Pharmaceutical media release, based on the clinical data from REMAIN-I, REMAIN-II , REMAIN-III studies Hengrui Medicines subsidiary Guangdong Hengrui Medicine Co., Ltd. received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, approving the companys independently developed Class 1 innovative drug
18 May 2023 Status changed from active, no longer recruiting to completed.
09 Jun 2022 Planned End Date changed from 28 Jun 2022 to 13 Sep 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com